Abstract
Tremendous progress has been made in the treatment of psoriasis owing to the successful use of translational medicine in the last two decades (Reid and Griffiths, 2020). Using targeted biologics, nearly 90% of patients with psoriasis can achieve a clear or almost clear response (Hawkes et al., 2018). Thus, it is timely to start thinking about the use of advanced endpoints for psoriasis clinical trials to drive the next level of innovation toward disease remission and, even more ambitiously, a cure.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
